[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367314-105":59,"doc-detail-367314-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","development-of-a-m6a-and-ferroptosis-related-lncrna-signature-for-forecasting-prognosis-and-treatment-response-in-cervical-cancer","Development of a m6A-and ferroptosis- related LncRNA signature for forecasting prognosis and treatment response in cervical cancer","","N6-methyladenosine (m6A) and ferroptosis influence cancer development and prognosis through long noncoding RNAs (lncRNAs). This study analyzes cervical cancer subtypes defined by m6A- and ferroptosis-related lncRNAs (mfr lncRNAs) and builds an mfr lncRNA signature to predict clinical outcomes and treatment response. Public datasets support subtype discovery and comparisons of prognosis, immune infiltration, and biological mechanisms, followed by prognostic factor identification, signature construction, and nomogram-based survival prediction. Quantitative PCR validates differential expression, and immune and drug sensitivity analyses assess risk-group differences.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/development-of-a-m6a-and-ferroptosis-related-lncrna-signature-for-forecasting-prognosis-and-treatment-response-in-cervical-cancer/367314/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/development-of-a-m6a-and-ferroptosis-related-lncrna-signature-for-forecasting-prognosis-and-treatment-response-in-cervical-cancer/367314.png","ImageObject",300,407,{"name":92,"@type":93},"Ophelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the goal of this study in cervical cancer?","Question",{"text":112,"@type":113},"To identify cervical cancer subtypes based on m6A- and ferroptosis-related lncRNAs and to construct an mfr lncRNA signature that predicts prognosis and treatment response.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were cervical cancer subtypes and the prognostic signature determined?",{"text":117,"@type":113},"Subtypes were identified using public datasets and compared by prognosis, immune infiltration, and biological mechanisms. A prognostic signature was then built from prognosis-related mfr lncRNAs.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the results show about risk groups and treatment response?",{"text":121,"@type":113},"The study developed a six-mfr lncRNA signature with strong prognostic performance. RiskScore and stage acted as independent prognostic factors, and low-risk patients showed more active immunotherapy responses and greater sensitivity to chemotherapeutic drugs such as imatinib.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367314,1790208008,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Wen et al. BMC Cancer (2025) 25:580 BMC Cancer  \n[https://doi.org/10.1186/s12885-025-13974-8](https://doi.org/10.1186/s12885-025-13974-8)  \nRESEARCH Open Access  \nDevelopment of a m6A-and ferroptosis- related LncRNA signature for forecasting prognosis and treatment response in cervical cancer  \nKaiting Wen 1, Lili Wang 1, Huancheng Su 1, Lijun Yu 1*, Sanyuan Zhang 1*, Meiyan Wei 1, Yaling Wang 1, Le Zhao 1 and Yan Guo 1  \nAbstract  \nBackground N6-methyladenosine (m6A) and ferroptosis are involved in the development and prognosis of various cancers via long noncoding RNAs (lncRNAs) . This study aimed to investigate the cervical cancer subtypes based on m6A-and ferroptosis-related lncRNAs (mfrl ncRNAs) and to construct a mfrlncRNA signature to predict cervical cancer prognosis and treatment response.  \nMethods mfrlncRNA-related cervical cancer subtypes were identified based on public datasets, and their differences in terms of prognosis, immune cell infiltration, and biological mechanisms were compared. Moreover, prognosisrelated mfrl ncRNAs were identified to construct a prognostic signature. A nomogram was constructed based on the independent prognostic factors. Immune characteristics, immunotherapy response predictions, and drug sensitivity analyses were performed for both risk groups. Furthermore, quantitative PCR was performed to validate the differential expression of the signature mfrlncRNAs in clinical samples.  \nResults In total, 549 differential ly expressed mfrl ncRNAs were identified between cervical cancer and normal samples. Two mfrlncRNA-related cervical cancer subtypes that exhibited distinct prognoses, immune characteristics, and biological mechanisms were identified. A prognostic signature was developed using six prognostic mfrl ncRNAs: AC016065. 1, AC096992.2, AC119427. 1, AC133644. 1, AL121944. 1, and FOXD1_AS1 . This prognostic signature exhibited high performance in predicting the prognosis of cervical cancer. Moreover, RiskScore and stage were identified as independent prognostic factors, and a nomogram was constructed to accurately forecast overall survival. Furthermore, patients in the low-risk group had a more active immunotherapy response and were more sensitive to chemotherapeutic drugs such as imatinib. Upregulated expression of AC119427. 1, AC133644. 1, AL121944. 1, and FOXD1_AS1 was observed in the tumor samples.  \n*Correspondence:  \nLijun Yu[yulijun100@163.com](yulijun100@163.com)[ ](yulijun100@163.com)Sanyuan Zhang [zsyprofessor@aliyun.com](zsyprofessor@aliyun.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \nWen et al. BMC Cancer (2025) 25:580 Page 2 of 16  \nConclusions The six-mfrlncRNA signature is a new biomarker for forecasting prognosis and treatment response in cervical cancer.  \nKeywords Cervical cancer, N6-methyladenosine, Ferroptosis, Long non-coding RNA, Prognostic signature  \nIntroduction  \nCe","cbCaid5Mnixh0bTm","https://ap.wps.com/l/cbCaid5Mnixh0bTm","pdf",3081327,16,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Epidemiology and clinical challenge\n## Role of lncRNAs and need for biomarkers","[{\"question\":\"What was the goal of this study in cervical cancer?\",\"answer\":\"To identify cervical cancer subtypes based on m6A- and ferroptosis-related lncRNAs and to construct an mfr lncRNA signature that predicts prognosis and treatment response.\"},{\"question\":\"How were cervical cancer subtypes and the prognostic signature determined?\",\"answer\":\"Subtypes were identified using public datasets and compared by prognosis, immune infiltration, and biological mechanisms. A prognostic signature was then built from prognosis-related mfr lncRNAs.\"},{\"question\":\"What did the results show about risk groups and treatment response?\",\"answer\":\"The study developed a six-mfr lncRNA signature with strong prognostic performance. RiskScore and stage acted as independent prognostic factors, and low-risk patients showed more active immunotherapy responses and greater sensitivity to chemotherapeutic drugs such as imatinib.\"}]","Development of a m6A-and ferroptosis- related LncRNA signature for forecasting prognosis and treatment response in cervical cancer | PDF",1790170199,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa90f5ad428b077798f5d15fc0bc5448.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3d7e6ebe3b9daea8c70f28d31a5caa8a.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3cf1557e1c9e37e458b55fe8c9f0abb9.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/900fde425fe57d5810f9dd6210980d7c.webp",980,1306]